510(k) Report

510(k) · Cleared

Cleared

Transpara (2.1.0)

K241831510(k) TraditionalCleared Nov 25, 2024153-day reviewClass II21 CFR 892.2090

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Screenpoint Medical B.V. · QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer

Cleared on Nov 25, 2024 as substantially equivalent to K221347 (Screenpoint Medical B.V., 2022) after a 153-day review. Its family tree reaches back 5 generations to 2018. 2 later devices descend from it.

Decided
Nov 25, 2024
Review
153 days
Class
Class II
Product code
QDQ
Recalls
None
Predicates
1

Its longest line of descent runs back 5 generations to DEN180005 (2018). 2 later devices descend from it, 2 citing it directly.

  1. Root · 5 generations backDEN180005 OsteoDetectImagen Technologies, Inc. · 2018
  2. 4 generations backK181704 TransparaScreenpoint Medical B.V. · 2018
  3. 3 generations backK193229 TransparaScreenpoint Medical B.V. · 2020
  4. 2 generations backK210404 Transpara 1.7.0Screenpoint Medical B.V. · 2021
  5. 1 generation backK221347 Transpara 1.7.2Screenpoint Medical B.V. · 2022
  6. This deviceK241831 Transpara (2.1.0)Screenpoint Medical B.V. · 2024
  7. Descendant · cites it directly · 0 of its ownK260898 Transpara (2.1.0)Screenpoint Medical B.V. · 2026
  8. Descendant · cites it directly · 0 of its ownK251474 Median LCS (internal name) / eyonis LCS (trade name) (1.0)Median Technologies · 2026

Most influential descendants

Showing 2 of 2 · See all
  • K260898Transpara (2.1.0)Screenpoint Medical B.V. · 2026 · cites it directly0descendants
  • K251474Median LCS (internal name) / eyonis LCS (trade name) (1.0)Median Technologies · 2026 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5DEN180005OsteoDetectImagen Technologies, Inc.2018—
−4K181704TransparaScreenpoint Medical B.V.2018—
−3K193229TransparaScreenpoint Medical B.V.2020—
−2K210404Transpara 1.7.0Screenpoint Medical B.V.2021—
−1K221347Transpara 1.7.2Screenpoint Medical B.V.2022—
0 (this device)K241831Transpara (2.1.0)Screenpoint Medical B.V.2024—
+1K260898Transpara (2.1.0)Screenpoint Medical B.V.2026—
+1K251474Median LCS (internal name) / eyonis LCS (trade name) (1.0)Median Technologies2026—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202620
FIG. 1 — Lineage of K241831, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QDQ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QDQ device

  1. #1 K260086 CadAI-B Dxscore 15.4 · 13 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K221347Transpara 1.7.2
Summary page 6
…CFR 892.2090 Panel Radiology Device class II Product code QDQ Clearance number K221347 4. Device description Transpara is a software only application designed to be used by physicians to improve interpretati…
Screenpoint Medical B.V.2022—

Also cleared against K221347: 1 other device →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K260898Transpara (2.1.0)Screenpoint Medical B.V.20260
K251474Median LCS (internal name) / eyonis LCS (trade name) (1.0)Median Technologies20260

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 6 years and passes through 2 companies; a new generation was cleared every 1.2 years on median.
  • None of the 5 ancestors has a recall.
  • Of its descendants, K260898 (Screenpoint Medical B.V., 2026) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K221347.

How does its category compare?

All QDQ devices

QDQ Radiological Computer Assisted Detection/Diagnosis Software For Lesions Suspicious For Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · QDQ

10so far in 2026, the most since 2007

2018: 22019: 22020: 32021: 52022: 42023: 22024: 72025: 52026 (partial year): 10
2007high 10 (2026) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QDQ

216in 2025

2020: 173 days median2021: 169 days median2022: 131 days median2024: 153 days median2025: 216 days median2026 (partial year): 154 days median
2007high 216 (2025) · low 131 (2022)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QDQ

No recall names QDQ since 2007.

Adverse event reports per year · QDQ

No MAUDE report names QDQ since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20182—00
20192—00
2020317300
2021516900
2022413100
20232—00
2024715300
2025521600
2026101540—

What is it indicated for?

Transpara software is intended for use as a concurrent reading aid for physicians interpreting screening full-field digital mammography exams and digital breast tomosynthesis exams from compatible FFDM and DBT systems, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. Output of the device includes locations of calcifications groups and soft-tissue regions, with scores indicating the likelihood that cancer is present, and an exam score indicating the likelihood that cancer is present in the exam. Patient management decisions should not be made solely on the basis of analysis by Transpara.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K241831: Transpara (2.1.0).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K241831

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026